TOMSICEK MICHAEL JOHN 4

What Happened
Michael J. Tomsicek, a director of Acrivon Therapeutics, was granted a derivative award on 2026-06-17 covering 20,275 shares. The grant is reported as an acquisition at $0.00 (derivative), meaning no cash was paid as part of this award. This is a grant/award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22 (filed after the usual two-business-day reporting window).
• Transaction type/code: A (Grant, award or other acquisition) — derivative security covering 20,275 shares at $0.00.
• Vesting: Per footnote, the shares subject to the option vest on the date immediately preceding the issuer’s next annual meeting of stockholders, contingent on continuous service.
• Shares owned after transaction: not disclosed in the provided filing.
• No 10b5-1 plan, tax-withholding, or immediate sale noted in the filing.

Context
This filing documents an equity award to a director rather than an open-market trade. Such grants are common for director compensation and do not by themselves indicate buying or selling sentiment. Because the award vests in the future (and the Form 4 was filed after the two-business-day window), retail investors should note timing and vesting conditions when assessing any potential impact.